BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37119247)

  • 1. ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia.
    Mohd Amin A; Panneerselvan N; Md Noor S; Mohtaruddin N; Sathar J; Norbaya WS; Osman R; Kee LH; Mohd Yaakub WH; Cheong SK; Abdullah M
    Malays J Pathol; 2023 Apr; 45(1):65-76. PubMed ID: 37119247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia.
    Kersten B; Valkering M; Wouters R; van Amerongen R; Hanekamp D; Kwidama Z; Valk P; Ossenkoppele G; Zeijlemaker W; Kaspers G; Cloos J; Schuurhuis GJ
    Br J Haematol; 2016 Apr; 173(2):219-35. PubMed ID: 26814163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
    Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
    Schuurhuis GJ; Meel MH; Wouters F; Min LA; Terwijn M; de Jonge NA; Kelder A; Snel AN; Zweegman S; Ossenkoppele GJ; Smit L
    PLoS One; 2013; 8(11):e78897. PubMed ID: 24244383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
    Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
    Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.
    Petersen MA; Rosenberg CA; Brøndum RF; Aggerholm A; Kjeldsen E; Rahbek O; Ludvigsen M; Hasle H; Roug AS; Bill M
    Br J Haematol; 2022 May; 197(4):452-466. PubMed ID: 35298835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
    Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.
    van Rhenen A; van Dongen GA; Kelder A; Rombouts EJ; Feller N; Moshaver B; Stigter-van Walsum M; Zweegman S; Ossenkoppele GJ; Jan Schuurhuis G
    Blood; 2007 Oct; 110(7):2659-66. PubMed ID: 17609428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells.
    Jaddaoui S; Bencharef H; Lamchahab M; Quessar A; Oukkache B
    Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.
    Bill M; Aggerholm A; Kjeldsen E; Roug AS; Hokland P; Nederby L
    Br J Haematol; 2019 Mar; 184(5):769-781. PubMed ID: 30520015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
    Herrmann H; Sadovnik I; Eisenwort G; Rülicke T; Blatt K; Herndlhofer S; Willmann M; Stefanzl G; Baumgartner S; Greiner G; Schulenburg A; Mueller N; Rabitsch W; Bilban M; Hoermann G; Streubel B; Vallera DA; Sperr WR; Valent P
    Blood Adv; 2020 Oct; 4(20):5118-5132. PubMed ID: 33085758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.
    Moshaver B; Wouters RF; Kelder A; Ossenkoppele GJ; Westra GAH; Kwidama Z; Rutten AR; Kaspers GJL; Zweegman S; Cloos J; Schuurhuis GJ
    Leuk Res; 2019 Jun; 81():27-34. PubMed ID: 31002948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
    Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
    Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
    Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
    Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
    Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.